Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts rate Medpace a "Hold" — the consensus from 15 brokerages is Hold (1 sell, 10 hold, 4 buy) with an average 12‑month price target of $467.08, and several firms (Weiss, Barclays, Truist, Zacks) have recently downgraded or lowered targets.
• Q1 results beat expectations — Medpace reported EPS of $4.28 vs. $3.74 estimate and revenue of $706.6M (up 26.5% YoY), and set FY2026 guidance of $16.68–17.50 EPS (analysts ~17.04).
• Legal and insider developments raise risk — a class action and multiple plaintiff solicitations allege securities-law violations after the company flagged rising cancellations, and President Jesse J. Geiger sold 31,707 shares (≈$14.4M), cutting his stake by ~67.9% while insiders own 20.5% of the stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has received an average recommendation of "Hold" from the fifteen brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $467.0833.

MEDP has been the subject of several recent analyst reports. Weiss Ratings downgraded Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, April 6th. Barclays lowered their price target on Medpace from $500.00 to $450.00 and set an "equal weight" rating for the company in a report on Friday, April 24th. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a "hold" rating for the company in a report on Wednesday, February 11th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Finally, Zacks Research cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 12th.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the firm's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC lifted its holdings in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in Medpace in the second quarter valued at approximately $296,000. Finally, M&T Bank Corp lifted its holdings in Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after acquiring an additional 31 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

Shares of MEDP stock opened at $417.54 on Friday. The company has a market cap of $11.92 billion, a P/E ratio of 26.24, a PEG ratio of 2.12 and a beta of 1.19. The stock's 50-day moving average is $468.91 and its 200 day moving average is $532.81. Medpace has a 1-year low of $284.10 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company's quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace will post 17.04 EPS for the current year.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Bares Capital trims its stake in Medpace, a portfolio move that may reflect manager rebalancing or concern about near-term risks. Bares Capital Trims Stake
• Negative Sentiment: A class action has been filed against Medpace and certain officers alleging violations of the federal securities laws for the period Apr 22, 2025–Feb 9, 2026; this formal filing increases legal exposure and investor uncertainty. Bronstein, Gewirtz & Grossman Class Action
• Negative Sentiment: Multiple plaintiff firms are actively soliciting lead plaintiffs and issuing investor alerts (Schall, Gross, BFA Law, Pomerantz, Rosen, Faruqi & Faruqi, Portnoy, Robbins, SueWallSt, Frank R. Cruz, Robbins LLP). The flurry of filings/solicitations heightens the probability of consolidated litigation, potential discovery, legal fees and settlement risk. Examples: Schall Law Firm Gross Law Firm BFA Law Pomerantz
• Negative Sentiment: Media coverage highlights that peers (Agios) posted strong results while reporting noted Medpace flagged rising cancellations—this operational disclosure appears to be the proximate cause of the stock weakness and underpins many litigation claims alleging the company misrepresented backlog/cancellation risks. Agios / Medpace Cancellations Coverage

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.